These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 8331552)

  • 1. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
    Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
    Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.
    Kubo K; Inada Y; Kohara Y; Sugiura Y; Ojima M; Itoh K; Furukawa Y; Nishikawa K; Naka T
    J Med Chem; 1993 Jun; 36(12):1772-84. PubMed ID: 8510105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.
    Noda M; Shibouta Y; Inada Y; Ojima M; Wada T; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
    Biochem Pharmacol; 1993 Jul; 46(2):311-8. PubMed ID: 8347154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
    Kubo K; Kohara Y; Imamiya E; Sugiura Y; Inada Y; Furukawa Y; Nishikawa K; Naka T
    J Med Chem; 1993 Jul; 36(15):2182-95. PubMed ID: 8340921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
    Kito G; Morimoto S; Shiomi M
    Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
    Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
    J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
    Wienen W; Mauz AB; Van Meel JC; Entzeroth M
    Mol Pharmacol; 1992 Jun; 41(6):1081-8. PubMed ID: 1614410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
    Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
    Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
    Nishikawa K; Inada Y; Shibouta Y; Wada T; Ojima M; Kubo K; Naka T
    Blood Press Suppl; 1994; 5():7-14. PubMed ID: 7889205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist.
    Cazaubon C; Gougat J; Bousquet F; Guiraudou P; Gayraud R; Lacour C; Roccon A; Galindo G; Barthelemy G; Gautret B
    J Pharmacol Exp Ther; 1993 May; 265(2):826-34. PubMed ID: 8496828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist.
    Wong PC; Hart SD; Chiu AT; Herblin WF; Carini DJ; Smith RD; Wexler RR; Timmermans PB
    J Pharmacol Exp Ther; 1991 Nov; 259(2):861-70. PubMed ID: 1941632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profiles of a novel non-peptide angiotensin II type I receptor antagonist HR720 in vitro and in vivo.
    Jin D; Song K; Oka Y; Takai S; Shiota N; Miyazaki M
    Jpn J Pharmacol; 1997 Nov; 75(3):259-66. PubMed ID: 9434257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.
    Robertson MJ; Barnes JC; Drew GM; Clark KL; Marshall FH; Michel A; Middlemiss D; Ross BC; Scopes D; Dowle MD
    Br J Pharmacol; 1992 Dec; 107(4):1173-80. PubMed ID: 1467838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
    Kito G; Ito K; Shiomi M
    Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
    Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
    Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CV-11974, the active metabolite of TCV-116 (Candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells.
    Sachinidis A; el-Haschimi K; Ko Y; Seul C; Düsing R; Vetter H
    Biochem Pharmacol; 1996 Jul; 52(1):123-6. PubMed ID: 8678895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist.
    Shibasaki M; Fujimori A; Takanashi M; Kusayama T; Tokioka T; Satoh Y; Okazaki T; Uchida W; Inagaki O; Yanagisawa I
    Eur J Pharmacol; 1997 Sep; 335(2-3):167-73. PubMed ID: 9369370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist.
    Hong KW; Kim CD; Lee SH; Yoo SE
    Fundam Clin Pharmacol; 1998; 12(1):64-9. PubMed ID: 9523186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.